Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark R Litzow

Showing results (21-30 of 456) with videos related to

Pageof 46
Sort By:
Expert Opinion on Pharmacotherapy|June 24, 2008
Arsenic trioxideMark R Litzow
Leukemia Research|August 5, 2009
TKIs and transplant for chronic myeloid leukemiaMark R Litzow
Blood and Lymphatic Cancer : Targets and Therapy|July 31, 2019
Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemiaMehrdad Hefazi, Mark R Litzow
Blood Advances|November 29, 2018
No free rides: management of toxicities of novel immunotherapies in ALL, including financialTania Jain, Mark R Litzow
Current Hematologic Malignancy Reports|June 28, 2018
Recent Advances in the Biology and Treatment of T Cell Acute Lymphoblastic LeukemiaMehrdad Hefazi, Mark R Litzow
Clinical Advances in Hematology & Oncology : H&O|September 22, 2025
Integration of immunotherapy into the frontline treatment of acute lymphoblastic leukemiaAjoy Dias, Mark R Litzow
Hematology. American Society of Hematology. Education Program|December 4, 2018
No free rides: management of toxicities of novel immunotherapies in ALL, including financialTania Jain, Mark R Litzow
Blood Advances|October 20, 2025
Immunotherapy in the Upfront Treatment of Adult B-cell Precursor Acute Lymphoblastic Leukemia: When, How, Who?Soumyadeep Datta, Mark R Litzow
Therapeutic Advances in Hematology|February 4, 2020
Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemiaTania Jain, Mark R Litzow
Blood and Lymphatic Cancer : Targets and Therapy|July 31, 2019
Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectivesTheodora Anagnostou, Mark R Litzow
Pageof 46

Showing results (21-30 of 456) with videos related to

Sort By:
Pageof 46
Expert Opinion on Pharmacotherapy|June 24, 2008
Arsenic trioxideMark R Litzow
Leukemia Research|August 5, 2009
TKIs and transplant for chronic myeloid leukemiaMark R Litzow
Blood and Lymphatic Cancer : Targets and Therapy|July 31, 2019
Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemiaMehrdad Hefazi, Mark R Litzow
Blood Advances|November 29, 2018
No free rides: management of toxicities of novel immunotherapies in ALL, including financialTania Jain, Mark R Litzow
Current Hematologic Malignancy Reports|June 28, 2018
Recent Advances in the Biology and Treatment of T Cell Acute Lymphoblastic LeukemiaMehrdad Hefazi, Mark R Litzow
Clinical Advances in Hematology & Oncology : H&O|September 22, 2025
Integration of immunotherapy into the frontline treatment of acute lymphoblastic leukemiaAjoy Dias, Mark R Litzow
Hematology. American Society of Hematology. Education Program|December 4, 2018
No free rides: management of toxicities of novel immunotherapies in ALL, including financialTania Jain, Mark R Litzow
Blood Advances|October 20, 2025
Immunotherapy in the Upfront Treatment of Adult B-cell Precursor Acute Lymphoblastic Leukemia: When, How, Who?Soumyadeep Datta, Mark R Litzow
Therapeutic Advances in Hematology|February 4, 2020
Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemiaTania Jain, Mark R Litzow
Blood and Lymphatic Cancer : Targets and Therapy|July 31, 2019
Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectivesTheodora Anagnostou, Mark R Litzow
Pageof 46